Vedolizumab IV
( DrugBank: Vedolizumab / KEGG DRUG: Vedolizumab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 12 |
| 96 | Crohn disease | 67 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 83 |
94. Primary sclerosing cholangitis
Clinical trials : 189 / Drugs : 159 - (DrugBank : 46) / Drug target genes : 22 - Drug target pathways : 148
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,888 / Drugs : 1,678 - (DrugBank : 247) / Drug target genes : 193 - Drug target pathways : 234
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. Ulcerative colitis
Clinical trials : 3,566 / Drugs : 2,369 - (DrugBank : 339) / Drug target genes : 210 - Drug target pathways : 245
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|